[1]李诗杨,殷彩琴,周 楠,等.“互联网+”背景下孤儿药可及性提升策略研究——基于长尾效应[J].卫生经济研究,2022,39(9):49-52.
　LI Shiyang,YIN Caiqin,ZHOU Nan,et al.Study on the Strategy of Improving the Accessibility of "Internet +" Orphan Drug——Based on the Long Tail Effect[J].Journal Press of Health Economics Research,2022,39(9):49-52.
点击复制

“互联网+”背景下孤儿药可及性提升策略研究
——基于长尾效应
分享到：

卫生经济研究[ISSN:1004-7778/CN:33-1056/F]

卷:
39
期数:
2022年9期
页码:
49-52
栏目:
药械管理
出版日期:
2022-08-30

文章信息/Info

Title:
Study on the Strategy of Improving the Accessibility of "Internet +" Orphan Drug
——Based on the Long Tail Effect
作者:
李诗杨1; 2; 殷彩琴2; 周 楠3; 唐国锋4; 石全胜2
1.重庆邮电大学网络社会发展问题研究中心，重庆 400065
2.重庆邮电大学现代邮政学院，重庆 400065
3.长江师范学院财经学院，重庆 408100
4.重庆工商大学管理科学与工程学院，重庆400067
Author(s):
LI Shiyang;  YIN Caiqin;  ZHOU Nan;  TANG Guofeng;  SHI Quansheng
Research Center on network social development, Chongqing University of Posts and Telecommunications, Chongqing 400065, China
关键词:
孤儿药; 长尾效应; 药物可及性; “互联网+”
Keywords:
orphan drug;  long tail effect;  drug accessibility;  "Internet +"
分类号:
R19
文献标志码:
A
摘要:
孤儿药的可及性是世界各国面临的共同难题。本文针对罕见病患病率低、患者分布分散的长尾特性，分析当前孤儿药在研发、生产和销售环节中存在的问题。通过对“互联网+”背景下患者群体易聚集、易交流等特性的剖析，以患者需求为出发点，反向重构孤儿药的研发、生产及销售路径，以期为提高孤儿药可及性提供借鉴。
Abstract:
The accessibility of orphan drugs is a common problem faced by countries all over the world. Aiming at the "long tail" characteristic of rare diseases with low prevalence and scattered patient distribution, this article analyzed the main problems in the development, production and sales of orphan drugs in detail. Through the analysis of the characteristics of easy aggregation and easy communication of patient groups under the background of "Internet +", this study started from the needs of patients, to reversely reconstruct the research and development, production and sales paths of orphan drugs, so as to provide reference for improving the accessibility of orphan drugs.

参考文献/References:

[1] 黄如芳，邵文斌.中国罕见病药物可及性报告2019[EB/OL].（2019-02-28）[2020-07-16].https://tech.sina.com.cn/roll/2020-02-27/doc-iimxyqvz6085831.shtml.
[2] 冀希炜，梁家彬，季双敏.罕见病治疗国内外的研究现状[J].中国临床药理学杂志，2019，35（3）：305-308.
[3] 刘鑫，李建涛，张鹏霄.中国孤儿药现状及与国外对比分析研究[J].中国药学杂志，2019，54（10）：839-846.
[4] Gong S,Wang Y,Pan X,et al.The availability and affordability of orphan drugs for rare diseases in China[J].Orphanet Journal of Rare Diseases,2016,11(1):20.
[5] Sardana D,Zhu C,Zhang M,et al.Drug repositioning for orphan diseases[J].Briefings in Bioinformatics,2011,12(4):346-356.
[6] Milne C,Ni W.The use of social media in orphan drug development[J].Clinical Therapeutics,2017,39(11): 2173-2180.
[7] Kakkar A K,Dahiya N.The evolving drug development landscape: from blockbusters to niche busters in the orphan drug space[J].Drug Development Research,2014,75(4):231-234.
[8] Douglas C M,Wilcox E,Burgess M M,et al.Why orphan drug coverage reimbursement decision-making needs patient and public involvement[J].Health Policy, 2015, 119(5): 588-596.
[9] 白桦，张抒扬.有关促进国内罕见病药物临床试验的几点建议[J].国际药学研究杂志，2019，46（9）：679-684.
[10] Cheng A,Xie Z.Challenges in orphan drug development and regulatory policy in China[J].Orphanet Journal of Rare Diseases,2017,12(1):13.
[11] Young A,Menon D,Street J M,et al. Exploring patient and family involvement in the lifecycle of an orphan drug: A scoping review[J].Orphanet Journal of Rare Diseases,2017,12(1):188.
[12] 王艳丽，都继萌，王帆.电商B2C模式下长尾理论的应用探索[J].商业经济研究，2017（17）：66-68.
[13] 赵云泽，蔡璐，杨若玉.“长尾效应”下自媒体营销方式探析[J].新闻记者，2016（9）：88-93.
[14] 郑壮丽.长尾理论与互联网时代科技期刊发展[J].中国科技期刊研究，2017，28（9）：810-814.
[15] Huang J S,Wang W.Application of the Long Tail economy to the online news market: examining predictors of market performance[J].Journal of Media Economics,2014,27(3):158-176.
[16] Li J,Zhang Y,Ma L,et al.The impact of the internet on health consultation market concentration: an econometric analysis of secondary data[J].Journal of Medical Internet Research,2016,18(10):e276. [17] 张夏恒.“互联网+”下医药电子商务生态系统的构建与发展路径[J].当代经济管理，2016，38（11）：26-29.
[18] Rodwell C,Ayme S.Rare disease policies to improve care for patients in Europe[J].Biochimica et Biophysica Acta,2015,1852(10):2329-2335.
[19] Shen T,Lee A,Shen C,et al.The long tail and rare disease research:the impact of next-generation sequencing for rare Mendelian disorders[J].Genetics Research,2015, 97(97):e15.

相似文献/References:

[1]胡善联.国内外罕见病的保障政策研究[J].卫生经济研究,2018,(05):3.
[2]李奕昊,唐贵忠.罕见病用药可负担性评价及医保政策研究[J].卫生经济研究,2022,39(4):53.
　LI Yi-hao,TANG Gui-zhong.Affordability Evaluation of Drugs for Rare Diseases and Research on Medical Insurance Policy[J].Journal Press of Health Economics Research,2022,39(9):53.
[3]陈子梦,王 丽,章 浴,等.基于供应链理论的我国孤儿药可及性分析与建议[J].卫生经济研究,2022,39(6):55.
　CHEN Zimeng,WANG Li,ZHANG Yu,et al.Analysis and Suggestions on the Accessibility of Orphan Medicines in China Based on Supply Chain Theory[J].Journal Press of Health Economics Research,2022,39(9):55.
[4]王珺琦,殷 悦,唐文熙.医保准入视角下罕见病用药经济价值评估的 难点、方法与建议[J].卫生经济研究,2024,41(09):58.
　WANG Junqi,YIN Yue,TANG Wenxi.Difficulties, Methods, and Suggestions for Assessing the Economic Value of Rare Disease Medications from the Perspective of Health Insurance Access[J].Journal Press of Health Economics Research,2024,41(9):58.

更新日期/Last Update: 2022-08-30